tiprankstipranks
Trending News
More News >
Oscar Health (OSCR)
NYSE:OSCR
US Market
Advertisement

Oscar Health (OSCR) AI Stock Analysis

Compare
1,937 Followers

Top Page

OSCR

Oscar Health

(NYSE:OSCR)

Rating:73Outperform
Price Target:
$19.00
▲(14.05% Upside)
Oscar Health's strong financial performance and positive technical indicators are the primary drivers of its stock score. However, the negative P/E ratio and operational challenges highlighted in the earnings call weigh down the overall score. The company's strategic initiatives and future profitability goals provide a cautiously optimistic outlook.
Positive Factors
Cash Flow Performance
Cash Flow CFO was $509MM, +2.4% y/y and well above the estimate of $135MM.
Cost Management
OSCR plans to eliminate $60mn of admin costs in 2026, which should drive ~50bp of margin.
Revenue Growth
OSCR raised revenue guidance to $12.0-$12.2B.
Negative Factors
Market Risk
Market risk scores are significantly higher than previously assumed, contributing to a cautious outlook.
Membership Decline
Expectations of disenrollment ranging from 20-50% of exchange membership will create a radically different risk pool.
Profitability Concerns
The pricing strategy for Oscar Health, Inc. does not appear adequate to produce stable margins in the current year.

Oscar Health (OSCR) vs. SPDR S&P 500 ETF (SPY)

Oscar Health Business Overview & Revenue Model

Company DescriptionOscar Health, Inc. (OSCR) is a technology-driven health insurance company focused on leveraging data and technology to enhance member experience and improve health outcomes. The company provides individual and family health insurance plans, small group insurance, and Medicare Advantage plans across the United States. Oscar Health differentiates itself through its consumer-oriented approach, telehealth services, and seamless digital platform that offers personalized care and support to its members.
How the Company Makes MoneyOscar Health makes money primarily through the collection of premiums from its members who enroll in its health insurance plans. The company's revenue streams include individual and family plans, small group plans, and Medicare Advantage plans. Oscar Health receives payments from members or sponsors, such as employers, who provide health insurance coverage. Additionally, the company may receive government subsidies for certain plans, particularly those offered under the Affordable Care Act. Oscar also generates revenue by managing healthcare utilization and costs effectively, as it shares in the savings if the cost of medical claims is lower than expected under value-based care arrangements. Partnerships with healthcare providers and a focus on preventive care and telemedicine also contribute to managing expenses and improving profitability.

Oscar Health Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 11, 2025
Earnings Call Sentiment Neutral
Oscar Health's earnings call highlighted significant revenue growth and strategic acquisitions, yet faced challenges with increased MLR, operational losses, and higher risk adjustment payables. The company's efforts to improve SG&A efficiency and expand through strategic partnerships are positive steps, but financial losses and market challenges weigh heavily.
Q2-2025 Updates
Positive Updates
Significant Revenue Growth
Oscar Health reported a total revenue of $2.9 billion for Q2 2025, representing a 29% increase year-over-year, driven by higher membership.
Membership Increase
The company ended the quarter with more than 2 million members, an increase of 28% year-over-year, driven by solid retention and above-market growth during open enrollment.
SG&A Efficiency
Oscar Health reported an improvement in the SG&A ratio by 90 basis points year-over-year to 18.7%, aided by lower exchange fee rates and fixed cost leverage.
Strategic Acquisitions and Partnerships
Oscar Health acquired new assets to enhance its consumer marketplace capabilities and announced a partnership with Hy-Vee to launch a new ICHRA product.
Negative Updates
Increased Medical Loss Ratio (MLR)
The MLR increased 12 points year-over-year to 91.1%, primarily driven by an overall increase in average market morbidity.
Operational Losses
Oscar Health reported a loss from operations of $230 million and an adjusted EBITDA loss of $199 million for Q2 2025.
Higher Risk Adjustment Payable
The risk adjustment payable for 2025 increased by $316 million due to higher ACA marketplace morbidity, impacting the company's financials.
Workforce Reduction
Oscar Health announced a reduction in workforce and administrative costs to manage operational expenses, expected to eliminate approximately $60 million in costs for 2026.
Company Guidance
During the Oscar Health Second Quarter 2025 Earnings Conference Call, the company provided several key metrics and guidance updates for the year. Oscar Health reported a total revenue of $2.9 billion for the second quarter, marking a 29% increase year-over-year. The medical loss ratio (MLR) increased by 12 points year-over-year to 91.1%, attributed to an increase in average market morbidity. The company reported a loss from operations of $230 million and an adjusted EBITDA loss of $199 million. For the first half of the year, earnings from operations were $66 million, and adjusted EBITDA was $129 million. Oscar reaffirmed its 2025 guidance, expecting revenue between $12 billion and $12.2 billion and a loss from operations ranging from $200 million to $300 million. They anticipate a full-year MLR between 86% and 87%. The SG&A expense ratio improved by 90 basis points year-over-year to 18.7%. The company is also taking measures to reduce administrative costs by about $60 million for 2026 and has improved its 2025 SG&A guidance by 50 basis points at the midpoint compared to initial guidance. Looking ahead, Oscar plans to return to profitability in 2026, driven by strategic pricing changes and expense management.

Oscar Health Financial Statement Overview

Summary
Oscar Health exhibits a positive financial trajectory, with substantial revenue growth, improving profitability metrics, and strong cash flow generation. The balance sheet is solid, with low leverage and improving equity. Despite some areas needing improvement, such as the equity ratio, the company is on a strong financial footing.
Income Statement
85
Very Positive
Oscar Health has demonstrated a strong revenue growth trajectory, with a significant increase in total revenue from $4.1 billion in 2022 to $10.08 billion in TTM (Trailing-Twelve-Months) 2025. The gross profit margin remains robust at 100%, indicating efficient cost management. Net profit margin has improved from negative figures to 1.22% in TTM 2025, showing progress towards profitability. EBIT and EBITDA margins have also improved, reflecting better operational efficiency.
Balance Sheet
75
Positive
The company's balance sheet shows a solid equity base, with stockholders' equity rising from negative in 2020 to $1.33 billion in TTM 2025. The debt-to-equity ratio is low at 0.22, indicating conservative leverage. Return on equity has turned positive, reflecting enhanced profitability. However, the equity ratio is at 22.81%, suggesting potential room for improvement in equity financing.
Cash Flow
80
Positive
Oscar Health has shown strong cash flow generation, with free cash flow increasing from negative figures to $1.19 billion in TTM 2025. The free cash flow to net income ratio is healthy, indicating efficient cash management. Operating cash flow to net income ratio is high, demonstrating the company's ability to convert earnings into cash effectively.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue9.18B5.86B4.13B1.92B589.64M
Gross Profit9.18B5.86B4.13B1.92B589.64M
EBITDA89.31M-212.00M-572.17M-551.25M-390.98M
Net Income25.43M-270.73M-606.27M-572.61M-406.82M
Balance Sheet
Total Assets4.84B3.60B4.53B3.32B2.27B
Cash, Cash Equivalents and Short-Term Investments2.15B2.56B2.96B1.69B1.19B
Total Debt299.56M298.78M298.00M0.00142.49M
Total Liabilities3.82B2.80B3.63B440.02M3.57B
Stockholders Equity1.01B803.97M890.38M1.39B-1.30B
Cash Flow
Free Cash Flow950.30M-297.74M351.34M-207.63M208.71M
Operating Cash Flow978.19M-272.16M380.35M-181.75M222.73M
Investing Cash Flow-1.39B577.19M-226.52M-774.51M-344.71M
Financing Cash Flow68.39M6.45M301.11M1.24B611.71M

Oscar Health Technical Analysis

Technical Analysis Sentiment
Positive
Last Price16.66
Price Trends
50DMA
16.11
Positive
100DMA
15.19
Positive
200DMA
15.03
Positive
Market Momentum
MACD
0.49
Negative
RSI
56.03
Neutral
STOCH
71.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSCR, the sentiment is Positive. The current price of 16.66 is above the 20-day moving average (MA) of 15.70, above the 50-day MA of 16.11, and above the 200-day MA of 15.03, indicating a bullish trend. The MACD of 0.49 indicates Negative momentum. The RSI at 56.03 is Neutral, neither overbought nor oversold. The STOCH value of 71.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OSCR.

Oscar Health Risk Analysis

Oscar Health disclosed 46 risk factors in its most recent earnings report. Oscar Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Oscar Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$4.24B49.61-14.04%48.29%-1436.25%
71
Outperform
$36.52B23.319.03%1.17%9.88%-7.25%
70
Outperform
$9.80B8.9223.93%16.12%10.99%
63
Neutral
$14.26B7.187.50%12.96%-23.25%
61
Neutral
$3.24B-38.50%49.46%66.89%
51
Neutral
$7.86B-0.26-41.41%2.22%22.87%-2.01%
50
Neutral
$1.34B-12.59%-4.87%66.16%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
OSCR
Oscar Health
16.66
-1.30
-7.24%
CNC
Centene
29.04
-51.19
-63.80%
HUM
Humana
303.66
-55.09
-15.36%
MOH
Molina Healthcare
180.83
-175.20
-49.21%
CLOV
Clover Health Investments
2.62
0.12
4.80%
ALHC
Alignment Healthcare
16.36
6.55
66.77%

Oscar Health Corporate Events

Executive/Board ChangesShareholder Meetings
Oscar Health Holds 2025 Annual Stockholders Meeting
Neutral
Jun 6, 2025

On June 4, 2025, Oscar Health, Inc. held its 2025 Annual Meeting of Stockholders, where a quorum was established with 825,961,296 votes represented. During the meeting, nine directors were elected, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025 was ratified. Additionally, the compensation of the company’s named executive officers was approved on an advisory basis, indicating shareholder support for the company’s leadership and financial oversight.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2025